Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
PrEP use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association.
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Tennessee Gov. Bill Lee made waves in early 2023, when he rejected millions of dollars in federal HIV prevention programming.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
(HealthDay News) — Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online in the Journal of the American Medical Association. Laura M. Mann ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback